Emcure Pharmaceuticals Ltd - Asset Resilience Ratio
Emcure Pharmaceuticals Ltd (EMCURE) has an Asset Resilience Ratio of 1.38% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Emcure Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See financial agility of Emcure Pharmaceuticals Ltd to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Emcure Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EMCURE market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs1.29 Billion | 1.38% |
| Total Liquid Assets | Rs1.29 Billion | 1.38% |
Asset Resilience Insights
- Limited Liquidity: Emcure Pharmaceuticals Ltd maintains only 1.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Emcure Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Emcure Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Tianjin Ringpu Bio Tech
SHE:300119 |
Drug Manufacturers - Specialty & Generic | 14.27% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Emcure Pharmaceuticals Ltd (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Emcure Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.92% | Rs760.43 Million ≈ $8.22 Million |
Rs82.33 Billion ≈ $890.34 Million |
-2.78pp |
| 2024-03-31 | 3.70% | Rs2.89 Billion ≈ $31.28 Million |
Rs78.06 Billion ≈ $844.21 Million |
+0.64pp |
| 2023-03-31 | 3.06% | Rs2.04 Billion ≈ $22.11 Million |
Rs66.73 Billion ≈ $721.61 Million |
+0.66pp |
| 2022-03-31 | 2.40% | Rs1.46 Billion ≈ $15.74 Million |
Rs60.63 Billion ≈ $655.74 Million |
-- |
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure X… Read more